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1. Introduction 
For several years we have used a radio-receptor 
assay to investigate the levels of endorphins in the 
cerebrospinal fluid (CSF) of patients. Correlations 
were established to, e.g., disease characteristics 
of chronic pain syndromes and various psychiatric 
disorders [ 11. It became apparent that the chemical 
identity to the active material was different from 
previously characterized endorphins: Here we present 
more extensive observations and chemical characteris- 
tics, particularly of fraction 1 (Fl) as in [2,3]. The 
strategy for the isolation has been to use the 
following procedures in sequence: 
(i) Analytical runs of Fl, isolated from the CSF of 
cases with well-defined clinical characteristics; 
(ii) Preparative scale separation of unspecified CSF 
obtained at neurosurgical procedures. 
It was found that the receptor-active material of 
Fl could be resolved into several (23) components 
by ion-exchange, molecular sieving and high- 
pressure liquid chromatography (HPLC). One 
component co-eluted with the dynorphin (l-l 3 j 
fragment and reacted with antibodies raised against 
that peptide; on a quantitative bases the receptor 
assay and the radioimmunoassay gave similar results. 
Also confirming the opioid character of material 
isolated from FI, was the observed activity on the 
guinea-pig ileum myenteric-plexus preparation. 
2. Material and methods 
Lumbar CSF from patients with various psychiat- 
ric disorders was the starting material in analytical 
runs while ventricular CSF obtained at neuro-surgical 
procedures was used in preparative runs. Met’- 
enkephalin and I_&-enkephalin were purchased from 
ElsevierlNorth-Holland Biomedical Press 
Bachem, /3-endorphin and dynorphin (1- 13) from 
Peninsula. Leu’-Arg6-enkephalin was synthesized 
and kindly donated by Dr Ulf Ragnarsson, Depart- 
ment of Biochemistry, University of Uppsala. 
[ 3H] Dihydromorphine at 75 Ci/mmol was purchased 
from the Radiochemical Centre, Amersham. All 
other chemicals were of reagent grade. 
The fractions were tested for opioid activity by a 
radio-receptor assay (RRA) using partially purified 
synaptic plasma membrane preparations from rat 
brain [4]. I-abelled dihydromorphine was the compet- 
ing radioligand. The activity was read as relative 
units; one relative unit being defined as the concen- 
tration of Met’-enkephalin giving a 50% inhibition 
of dihydromorphine binding. 
Radioimmunoassay was performed with the 
charcoal absorption technique. The antisera used 
were prepared at this laboratory for the enkephalins 
and fi-endorphin. The antiserum directed against 
dynorphin (l-l 3) was kindly donated by Professor 
Avram Goldstein Department of Pharmacology, 
Stanford University, Palo Alto., CA [5]. 
Analytical runs isolating Fl endorphins were 
performed as in [6]. The purification steps included 
ultrafiltration and chromatography on a Sephadex 
G-l 0 column (50 X 2 cm) in 0.2 M acetic acid 
(fractionation step A). For preparation scale purifica- 
tion of endorphins, a pool of CSF (30-300 ml) from 
several patients was lyophilized and reconstituted in 
0.2 M pyridine acetate buffer of pH 5. Material from 
analytical or preparative runs was fractionated on a 
SP-Sephadex C-25 ion-exchange column (fractiona- 
tion step B) with step-wise elution with 100 ml 0.2 M 
(fraction Ba), 150 ml 0.5 M (fraction Bb) and finally 
150 ml 2 M (fraction Bc) pyridine-acetate buffer solu- 
tions of pH 5.0. 
The active material from each fraction was further 
purified on a Biogel P2 column (160 X 1 cm), which 
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was eluted with 0.1% trifluoroacetic acid (TFA) 
(fractionation step C) yielding two major fractions of 
activity (fractions Ca and Cb, respectively, cf. fig. 1). 
The final fractionation step (D) was HPLC chromatog- 
raphy on a reversed-phase+Bondapak Cis column 
(3.9 X 300 mm, Waters) in a methanol/water/TFA 
gradient (starting buffer 30% methanol in water 
titrated to pH 3; final buffer 80% methanol in water 
titrated to pH 3; gradient time 30 min). Three differ- 
ent peaks of activity Da, Db and DC with retention 
times 12.5, 16.5 and 21.5 min, respectively, were 
isolated (cf. fig.2). 
Bioassay of opioid material in the guinea-pig ileum 
longitudinal muscle myenteric-plexus preparation 
followed standard procedures [7]. The preparation 
was placed in a 5 ml bath stimulated supramaximally 
at 0.1 Hz. Contractions were recorded isotonically. 
In each run a standard curve with graded concentra- 
tions of normorphine was run. 
3. Results 
During this work, availability of CSF samples 
varied. The preparative runs omitted the isolation of 
FI from the Sephadex G-10 column (step A). 
Table 1 
Identification of fractions Bc and Ca as functionally relevant, 
and related to activity measured in FI 
Fractionation Fraction CSF samplea 
step 
12 34 5 6 
A. 
Sephadex G-10 FI 42 -b - 4.4 1.2 - 
B. 
SP-Sephadex Bb 9 36 20 - - 40 
Bc 31 176 63 - - 60 
C. 
Biogel P2 Ca - - - 4.3 1.5 48 
Cb _ _ - 0.4 0.6 1.5 
a Origin of CSF samples: (1) schizophrenics (patient number, 
n=lO; total vol. 30 ml); (2,3) schizophrenics (n=3), before 
(2) and after (3) treatment with neuroleptics (22 ml each); 
(4,5) patients with chronic pain (n=3), before (4) and after 
(5) transcutaneous nerve stimulation (14 ml each); (6) pre- 
parative run of ventricular CSF (n=2; 200 ml) 
b Not tested 
A preparative run (6) not starting from FI was included for 
comparison. The table gives endorphin activity in total 
relative units measured in receptor assay 
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3.1. Analytical runs of FI 
It was necessary to introduce separation steps of 
high capacity before high resolution procedures like 
HPLC. A number of CSF samples from patients with 
specified clinical diagnoses were included. In two 
series, with schizophrenics and patients with 
chronic pain, respectively, each patient delivered 
samples before and after a treatment procedure 
known to change FI content. Fractionation step B 
(table 1) isolated most receptor active material in the 
2 M pyridine acetate fraction while most of remaining 
salts and UV-absorbing material was removed. Recep- 
tor-active material in the Ba and Bb fractions showed 
no distinct pattern on further chromatography; 
they were therefore not studied further. The material 
in the Bc fraction was run on a Biogel P2 column for 
further fractionation. The fractionation pattern 
revealed the presence of several components with 
most activity eluting in the 1500-2000 M, range 
(fig.1). The activity recovered at this step seems to 
represent most of the activity present in the original 
FI fraction (cf. CSF samples 4,5). Also in the pre- 
parative run (sample 6) most of the activity from step 
B, fraction Bc, was recovered in fractions 40-45 (Ca) 
on Biogel P2. 
3.2. Preparative scale separation 
The active material in fraction Ca was subjected to 
further purification on a reversed phase HPLC 
column. A linear gradient was run in methanol/water/ 
“0 B-end 
I I 
Leu!ArgB-ENK Leu-ENK 
i 
I I 
k 10 20 30 40 50 60 70 
Fract,on number 
Fig.1. Chromatography of material from ventricular CSF on 
a Biogel P2 column (160 X 1 cm) in 0.1% TFA. The fractions 
were assayed for opioid activity in a receptor assay The 
arrows indicate elution volumes of standard substances. 
bovine serum albumin, M, 60 000; p-endorphin Mr 3500; 
bacitracin,M, 1411; Lerr-Arg6-enkephalin,M, 712; Leu’- 
enkephalin, Mr 574. 
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Fig.2. Chromatography of material from ventricular CSF on a 
p-Bondapack C,, column. The samples were eluted in a linear 
gradient methanol/water/TFA at pH 3 for 30 min. Fractions 
of 1 ml (flowrate 1 ml/min) were individually assayed for 
opioid activity in a receptor assay and in a radioimmunoassay 
against dynorphin (1 - 13) directed antibodies. The upper 
curve shows the elution pattern of standard substances: (1) 
LeuS-Arg6-enkephalin; (2) Met’-enkephalin; (3) dynorphin 
(l-13); (4) p-endorphin. 
Table 2 
Fractionation of opioid activity from ventricular CSF on a 
preparative scale 
Fractionation Fraction Run 
step 
1 2 
B. 
SP-Sephadex Bc 60 51 
C. 
Biogel P2 Ca 48 30 
D. 
HPLC Da 4.6 12 
Db 1.6 13 
DC 2.8 13 
The table gives endorphin activity in total relative units in 
receptor assay 
Relative amounts of receptoractive material (RRA) or 
material active in dynorphin radioimmunoassay (RIA) in 
fractions isolated by HPLC (step D) 
HPLC Activity in RRA / Activity in RIA 
fraction 
Preparative runs Fraction 
I 
1 2 
D. a 0.61/0.63 0.72/0.60 0.2310.20 
b 0.61/<0.2 _a <O.l/ - 
C 0.68/<0.2 0.39lO.39 0.171 - 
a Not tested 
All values are expressed as pmol dynorphin (l -13)/sample 
which was used as the standard 
TFA and three peaks with active material were eluted 
(fig.2). Table 2 shows the distribution of the active 
material in two runs of ventricular CSF. The reason 
for the poor total recovery in the first run is not 
known. 
3.3. Identification of receptor-active material in 
radioimmunoassay 
The different HPLC fractions were tested against 
antibodies for Met’- and Leus-enkephalin, fl-endor- 
phin and dynorphin (l-l 3). The only positive results 
were obtained with antibodies directed against dynor- 
phin (table 3). Two preparative runs and one run 
starting from FI material gave consonant findings for 
fraction Da, which in receptor assay and radio- 
immunoassay gave comparable results on a molar 
basis, using dynorphin (1- 13) as the standard. The 
situation for the Db and DC fractions is less clear - in 
the second preparative run, the active material may 
be related to dynorphin. 
3.4. Bioassay of the Biogel P2 fiactions from 
ventricular CSF 
Material from fraction Ca was tested on the 
electrically stimulated guinea-pig ileum, where it 
showed inhibitory activity as the standard, normor- 
phine. This activity was partially reversed by 
naloxone (tig.3). Material from 75 ml ventricular CSF 
gave an inhibition equal to that produced by 
2 X lo-’ M normorphine, which on this preparation 
gave 50% inhibition of the twitch. 
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Fig.3. Inihibition of the electrically induced twitch of the 
guinea-pig ileum longitudinal muscle myenteric-plexus 
preparation by fraction Ca eluting from the Biogel P2 
column: S (sample) marks the addition of fraction Ca; 3 S 
the addition of the same fraction at 3-times higher concentra- 
tion; W marks washing; and N the addition of naloxone to 
final cont. 1Om6 M. 
phalins, (Y-, fl- or r-endorphin [5]. The possible 
existence of dynorphin in CSF is of considerable 
interest. This peptide has been isolated from porcine 
brain and pituitary. It shows extraordinary potency 
in most bioassays [lo] and it may therefore be func- 
tionally relevant even at very low concentrations. The 
identity of the other HPLC fractions is unclear as is 
their relation to known opioid peptide systems. Work 
is in progress to isolate enough material of these sub- 
fractions to facilitate chemical characterization. CSF 
samples need to be collected from different patient 
categories to establish which pattern of activity is 
characteristic for each category. 
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4. Discussion 
The purpose of this study was to find out, which 
opioid receptor-binding components are present in 
FI, defined in a radio-receptor assay with dihydro- 
morphine as the radioligand. As a guideline, we 
compared samples where we had observed correla- 
tions between FI levels and different clinical classifi- 
cations or disease characteristics with or without 
treatment modifications. We have found that trans- 
cutaneous nerve stimulation in chronic pain patients 
increases [8], and neuroleptic medication in 
schizophrenics decreases [9] total FI activity. Pre- 
and post-treatment CSF from patients where such 
therapy had been carried out was therefore compared. 
The analytical runs revealed that fraction Ca from 
the Biogel P2 column retained most FI activity. This 
fraction gave no reaction with antibodies directed 
against the enkephalins or fl-endorphin, which was 
expected since these peptides are known to be 
eliminated in previous steps of the fractionation 
procedure. The estimated Mr is -1500-2000 con- 
firming [2,3]. The material could also be character- 
ized as opioid on the guinea -pig ileum - although the 
inhibition of the twitch was not completely reversed 
by naloxone. 
The HPLC step revealed >3 major fractions of 
activity. The fraction Da might well be dynorphin or 
a fragment thereof, it gave very similar calculated 
molar quantities in the radio-receptor assay or radio- 
immunoassay when using dynorphin (1- 13) as the 
standard and it also co-migrated with this compound. 
The antibody shows no cross-reactivity with enke- 
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